Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.

Szczegóły
Abstrakt

Tytuł:: Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Autorzy:: Kobayashi M; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Sato R; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Komura T; Department of Surgery, Omagari Kousei Medical Center, Akita, Akita, Japan.
Ichikawa H; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Hirashima T; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Otake S; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Akazawa N; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Yazawa T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Abe T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Okada T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Kakita T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Oikawa M; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Tsuchiya T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan. .
Źródło:: International journal of clinical oncology [Int J Clin Oncol] 2020 Oct; Vol. 25 (10), pp. 1814-1821. Date of Electronic Publication: 2020 Jun 27.
Typ publikacji:: Journal Article; Randomized Controlled Trial
Język:: English
Imprint Name(s):: Publication: 1998- : Tokyo : Springer-Verlag Tokyo
Original Publication: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996-
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Colorectal Neoplasms/*drug therapy
Glutamates/*administration & dosage
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Peripheral Nervous System Diseases/*prevention & control
Administration, Oral ; Aged ; Cystine/administration & dosage ; Female ; Fluorouracil/adverse effects ; Humans ; Leucovorin/adverse effects ; Male ; Middle Aged ; Organoplatinum Compounds/adverse effects ; Oxaliplatin/administration & dosage ; Pilot Projects ; Quality of Life
References:: Support Care Cancer. 2006 May;14(5):484-7. (PMID: 16450089)
Ann Oncol. 1997 Jun;8(6):569-73. (PMID: 9261526)
Int J Gynecol Cancer. 2003 Nov-Dec;13(6):741-8. (PMID: 14675309)
Int J Clin Oncol. 2016 Dec;21(6):1085-1090. (PMID: 27306219)
J Clin Oncol. 2015 Oct 20;33(30):3416-22. (PMID: 26282635)
J Clin Oncol. 2002 Aug 15;20(16):3478-83. (PMID: 12177109)
J Clin Oncol. 2014 Jun 20;32(18):1941-67. (PMID: 24733808)
Oncologist. 2007 Mar;12(3):312-9. (PMID: 17405895)
Int J Clin Oncol. 2018 Feb;23(1):1-34. (PMID: 28349281)
Semin Oncol. 2006 Feb;33(1):15-49. (PMID: 16473643)
Gan. 1980 Oct;71(5):637-43. (PMID: 7227714)
Support Care Cancer. 2009 Aug;17(8):1071-80. (PMID: 19089463)
Anticancer Drugs. 2009 Jun;20(5):396-402. (PMID: 19287306)
Am J Physiol Cell Physiol. 2001 Dec;281(6):C1964-70. (PMID: 11698255)
Ann Oncol. 1998 Jul;9(7):739-44. (PMID: 9739440)
J Peripher Nerv Syst. 2007 Sep;12(3):210-5. (PMID: 17868248)
J Korean Med Sci. 2005 Oct;20(5):721-6. (PMID: 16224142)
Wien Klin Wochenschr. 2000 Jul 28;112(14):617-23. (PMID: 11008323)
J Clin Oncol. 1995 Jan;13(1):26-32. (PMID: 7799029)
N Engl J Med. 2004 Jun 3;350(23):2343-51. (PMID: 15175436)
Cancer. 2014 Jun 15;120(12):1890-7. (PMID: 24619793)
Nature. 1966 Jun 25;210(5043):1358-60. (PMID: 5963767)
Ann Oncol. 2000 Nov;11(11):1477-83. (PMID: 11142489)
Oncol Nurs Forum. 2017 May 1;44(3):E111-E123. (PMID: 28635977)
Ann Oncol. 2015 Jan;26(1):141-148. (PMID: 25316259)
J Oncol. 2019 Aug 1;2019:4828563. (PMID: 31467537)
Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. (PMID: 16806962)
Contributed Indexing:: Keywords: Amino acid; CIPN; Colorectal cancer; Cystine; Neuropathy; Oxaliplatin; Theanine
Substance Nomenclature:: 0 (Glutamates)
0 (Organoplatinum Compounds)
04ZR38536J (Oxaliplatin)
48TCX9A1VT (Cystine)
8021PR16QO (theanine)
Q573I9DVLP (Leucovorin)
U3P01618RT (Fluorouracil)
SCR Protocol:: Folfox protocol
Entry Date(s):: Date Created: 20200629 Date Completed: 20201125 Latest Revision: 20201125
Update Code:: 20240105
PubMed Central ID:: PMC7498479
DOI:: 10.1007/s10147-020-01728-4
PMID:: 32594273
: Czasopismo naukowe

Full Text Finder

Background: Oxaliplatin, one of the key cytotoxic drugs for colorectal cancer, frequently causes peripheral neuropathy which leads to dose modification and decreased patients' quality of life. However, prophylactic or therapeutic measures have not yet been established. Orally administered amino acids, cystine and theanine, promoted the synthesis of glutathione which was one of the potential candidates for preventing the neuropathy. The aim of this study was to determine whether daily oral administration of cystine and theanine attenuated oxaliplatin-induced peripheral neuropathy (OXLIPN).
Methods: Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group. OXLIPN was assessed up to the sixth course using original 7-item questionnaire as well as Common Terminology Criteria for Adverse Events (CTCAE) grading scale.
Results: Neuropathy scores according to our original questionnaire were significantly smaller in the cystine and theanine group at the fourth (p = 0.026), fifth (p = 0.029), and sixth course (p = 0.038). Furthermore, significant differences were also observed in CTCAE neuropathy grades at the fourth (p = 0.037) and the sixth course (p = 0.017). There was one patient in each group who required dose reduction due to OXLIPN. Except for neurotoxicity, no significant differences were noted in the incidence of adverse events, and the total amount of administered oxaliplatin.
Conclusion: The results demonstrated the daily oral administration of cystine and theanine attenuated OXLIPN.

Informacja